Viatris Inc (VTRS)
About Viatris Inc
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $14.3B
- Net income
- $0
- Total assets
- $37.2B
- Market cap
- $18.5B
- Gross margin
- 35.1%
- Operating margin
- -18.6%
- Net margin
- -24.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $14.3B
- Cost of revenue
- $9.3B
- Gross profit
- $5.0B
- Operating expenses
- $7.7B
- Operating income
- -$2.7B
- Income tax
- -$150.1M
- Net income
- -$3.5B
- EPS (basic)
- $-3.00
- EPS (diluted)
- $-3.00
Balance sheet
- Total assets
- $37.2B
- Current assets
- $9.8B
- Total liabilities
- $22.5B
- Current liabilities
- $7.1B
- Shareholders’ equity
- $14.7B
Cash flow
- Operating cash flow
- $2.3B
- Investing cash flow
- -$427.7M
- Financing cash flow
- -$1.3B
- Net cash flow
- $611.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $18.5B
- EPS (diluted)
- $-3.0
- Dividend yield
- 2.78%
- Shares outstanding
- 1.1B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 23, 1973
Viatris Inc (VTRS) Stock Price
- Revenue grew 20% from FY2020 to FY2025.
- Gross margin of 35.1%, net margin -24.6%.
- Trading near its 52-week high.
- Pays a dividend yielding about 2.78% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Viatris Inc.
Write a review
News about Viatris Inc
News & sentiment via Polygon.io
Viatris Inc: frequently asked questions
Is Viatris Inc an American company?
Yes — Viatris Inc is an American company headquartered in Canonsburg, Pennsylvania. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Viatris Inc headquartered?
Viatris Inc is headquartered in Canonsburg, Pennsylvania, United States.
Is Viatris Inc publicly traded?
Yes — Viatris Inc is a publicly traded company. Its stock trades under the ticker symbol VTRS on the NASDAQ.
What does Viatris Inc do?
Viatris Inc is an American Pharmaceuticals company in the Health & Beauty sector.
When was Viatris Inc founded?
Viatris Inc was founded in 2020.
